Impact of chronic doxycycline treatment in the APP/PS1 mouse model of Alzheimer's disease

[1]  P. Dutar,et al.  P2X7-deficiency improves plasticity and cognitive abilities in a mouse model of Tauopathy , 2021, Progress in Neurobiology.

[2]  Tzu-Hao Chang,et al.  CCL5 promotion of bioenergy metabolism is crucial for hippocampal synapse complex and memory formation , 2021, Molecular Psychiatry.

[3]  K. Blennow,et al.  Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease , 2020, Brain : a journal of neurology.

[4]  Zhengping Jia,et al.  The Role of ADF/Cofilin in Synaptic Physiology and Alzheimer’s Disease , 2020, Frontiers in Cell and Developmental Biology.

[5]  T. Owens,et al.  Protective Microglial Subset in Development, Aging, and Disease: Lessons From Transcriptomic Studies , 2020, Frontiers in Immunology.

[6]  C. Giampà,et al.  Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington’s Disease , 2019, Molecular Neurobiology.

[7]  R. Raisman‐Vozari,et al.  The Neuroprotective Effect of Doxycycline on Neurodegenerative Diseases , 2019, Neurotoxicity Research.

[8]  M. Gobbi,et al.  Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models , 2018, Neurobiology of Aging.

[9]  L. Buée,et al.  Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease , 2018, Front. Mol. Neurosci..

[10]  Luc Buée,et al.  Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies? , 2018, Biomedical journal.

[11]  Hui Zheng,et al.  Practical considerations for choosing a mouse model of Alzheimer’s disease , 2017, Molecular Neurodegeneration.

[12]  M. Korte,et al.  Not just amyloid: physiological functions of the amyloid precursor protein family , 2017, Nature Reviews Neuroscience.

[13]  Myeong Ok Kim,et al.  Neuroprotective Effect of Fisetin Against Amyloid-Beta-Induced Cognitive/Synaptic Dysfunction, Neuroinflammation, and Neurodegeneration in Adult Mice , 2017, Molecular Neurobiology.

[14]  Activation of phagocytic activity in astrocytes by reduced expression of the inflammasome component ASC and its implication in a mouse model of Alzheimer disease , 2016, Journal of Neuroinflammation.

[15]  P. Dutar,et al.  The Chemokine MIP-1α/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory , 2015, Scientific Reports.

[16]  K. Zahs,et al.  Characterization of a Novel Mouse Model of Alzheimer’s Disease—Amyloid Pathology and Unique β-Amyloid Oligomer Profile , 2015, PloS one.

[17]  Wei Zhang,et al.  Inhibition of c‐Jun N‐terminal kinase activation reverses Alzheimer disease phenotypes in APPswe/PS1dE9 mice , 2015, Annals of neurology.

[18]  O. Garaschuk,et al.  Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.

[19]  E. Weeber,et al.  RanBP9 at the intersection between cofilin and Aβ pathologies: rescue of neurodegenerative changes by RanBP9 reduction , 2015, Cell Death and Disease.

[20]  M. Gobbi,et al.  Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial , 2014, The Lancet Neurology.

[21]  R. Cunha,et al.  Predominant loss of glutamatergic terminal markers in a β-amyloid peptide model of Alzheimer's disease , 2014, Neuropharmacology.

[22]  N. Toni,et al.  Doxycycline increases neurogenesis and reduces microglia in the adult hippocampus , 2013, Front. Neurosci..

[23]  D. Molloy,et al.  A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial , 2013, International journal of geriatric psychiatry.

[24]  D. Kang,et al.  Pivotal role of the RanBP9-cofilin pathway in Aβ-induced apoptosis and neurodegeneration , 2012, Cell Death and Differentiation.

[25]  N. Greig,et al.  Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease , 2012, Journal of Neuroinflammation.

[26]  Wei Zhang,et al.  Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: involvement of oxidative stress and cholinergic dysfunction. , 2012, Free radical biology & medicine.

[27]  E. Speretta,et al.  Testing the Therapeutic Potential of Doxycycline in a Drosophila melanogaster Model of Alzheimer Disease* , 2011, The Journal of Biological Chemistry.

[28]  Akane Sano,et al.  Contextual learning requires synaptic AMPA receptor delivery in the hippocampus , 2011, Proceedings of the National Academy of Sciences.

[29]  D. Gruol,et al.  Chronic exposure to the chemokine CCL3 enhances neuronal network activity in rat hippocampal cultures , 2010, Journal of Neuroimmunology.

[30]  S. Doglia,et al.  Tetracycline and its analogues protect Caenorhabditis elegans from β amyloid-induced toxicity by targeting oligomers , 2010, Neurobiology of Disease.

[31]  H. C. Hartzell,et al.  ADF/Cofilin-Mediated Actin Dynamics Regulate AMPA Receptor Trafficking during Synaptic Plasticity , 2010, Nature Neuroscience.

[32]  M. Giustetto,et al.  Learning, AMPA receptor mobility and synaptic plasticity depend on n‐cofilin‐mediated actin dynamics , 2010, The EMBO journal.

[33]  K. J. Murphy,et al.  AAV‐mediated chronic over‐expression of SNAP‐25 in adult rat dorsal hippocampus impairs memory‐associated synaptic plasticity , 2010, Journal of neurochemistry.

[34]  G. Forloni,et al.  The Efficacy of Tetracyclines in Peripheral and Intracerebral Prion Infection , 2008, PloS one.

[35]  R. Sprengel,et al.  Tetracycline-controlled genetic switches. , 2007, Handbook of experimental pharmacology.

[36]  Brian J. Bacskai,et al.  Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease , 2006, Neurobiology of Disease.

[37]  M. Esiri,et al.  Down‐regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease , 2006, Journal of neurochemistry.

[38]  E. Mandelkow,et al.  Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy , 2006, Journal of Biological Chemistry.

[39]  D. Borchelt,et al.  Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Relationships to β-amyloid deposition and neurotransmitter abnormalities , 2005, Neurobiology of Disease.

[40]  Carlos Matute,et al.  Neuroprotection by tetracyclines. , 2004, Trends in pharmacological sciences.

[41]  Michael Borrie,et al.  A Randomized, Controlled Trial of Doxycycline and Rifampin for Patients with Alzheimer's Disease , 2004, Journal of the American Geriatrics Society.

[42]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[43]  D. Borchelt,et al.  Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. , 2001, Biomolecular engineering.

[44]  G. Forloni,et al.  Anti‐amyloidogenic activity of tetracyclines: studies in vitro , 2001, FEBS letters.